Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.8.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Revenues $ 122 $ 135
Operating expenses:    
Research and development (related parties of $176 and $239), net of $44 and $36 in grant income 985 820
General and administrative (related parties of $206 and $175) 2,498 2,469
Total operating expenses 3,483 3,289
Operating loss (3,361) (3,154)
Other income (expense):    
Interest expense (related party of $480 and $483) (480) (483)
Interest income 5 13
Royalty income 9 12
Total other income (expense) (466) (458)
Consolidated net loss (3,827) (3,612)
Net loss attributable to noncontrolling interest 1 551
Net loss attributable to iBio, Inc. (3,826) (3,061)
Preferred stock dividends (66) 0
Net loss available to iBio, Inc. (3,892) (3,061)
Comprehensive loss:    
Consolidated net loss (3,827) (3,612)
Other comprehensive loss - foreign currency translation adjustments 0 0
Comprehensive loss $ (3,827) $ (3,612)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.04) $ (0.03)
Weighted-average common shares outstanding - basic and diluted 91,853 89,109